Growth Metrics

Aurinia Pharmaceuticals (AUPH) Change in Accured Expenses (2020 - 2025)

Aurinia Pharmaceuticals' Change in Accured Expenses history spans 6 years, with the latest figure at $13.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 24.88% year-over-year to $13.1 million; the TTM value through Dec 2025 reached -$4.7 million, down 134.92%, while the annual FY2025 figure was -$4.7 million, 134.92% down from the prior year.
  • Change in Accured Expenses reached $13.1 million in Q4 2025 per AUPH's latest filing, up from -$641000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $17.5 million in Q4 2024 to a low of -$23.4 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $1.3 million, with a median of $539000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: tumbled 675.61% in 2021, then soared 5931.36% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.9 million in 2021, then crashed by 78.95% to $616000.0 in 2022, then plummeted by 44.48% to $342000.0 in 2023, then soared by 5007.89% to $17.5 million in 2024, then decreased by 24.88% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Change in Accured Expenses are $13.1 million (Q4 2025), -$641000.0 (Q3 2025), and $6.3 million (Q2 2025).